F.I.S. Fabbrica Italiana Sintetici S.p.A.

FIS is a leading Italian company and one of the top players in Europe in the development and production of Active Pharmaceutical Ingredients (APIs) for the global pharmaceutical industry. It is recognised internationally as a benchmark in the Contract Development and Manufacturing Organisation (CDMO) sector.

Founded in 1957 in Montecchio Maggiore (VI), FIS operates globally through three plants in Italy (Montecchio Maggiore, Termoli, and Lonigo), offices in North America and Japan, and an operational presence in China and India. The company offers integrated services to pharmaceutical clients covering the entire development cycle – from synthesis process optimisation and scale-up to large-scale production. Its core business is the exclusive manufacture of intermediates, advanced intermediates, and active pharmaceutical ingredients for patent-holding pharmaceutical companies (Custom Synthesis), as well as for the generic and veterinary markets.

In 2024, FIS reported revenues of €812 million (934M$), with a client portfolio spanning 60 countries.

With a production capacity exceeding 3,150 cubic metres and a workforce of 2,300 employees – more than 250 of whom are dedicated to Research & Development – FIS has built a strong market position over time. This is grounded in its continuous innovation, outstanding scientific expertise, a steadfast commitment to quality and safety across all processes, and a strong focus on sustainability.

In 2023, Bain Capital became the majority shareholder, taking over from the Ferrari family, the company’s founders. The move aims to further strengthen and fully leverage FIS’s strong growth potential. In April 2024, Daniele Piergentili was appointed as President and Chief Executive Officer.

Since 2017, FIS has published its Sustainability Report in line with GRI (Global Reporting Initiative) standards. Sustainability is a core value for FIS, serving as a genuine driver of growth and competitiveness. The company has integrated ESG objectives into its 2023–2025 Strategic Plan, with measurable goals validated by Sustainalytics and aligned with the Sustainability-Linked Bond Principles and Climate Transition Finance. Its strong commitment to sustainability led to the successful issue of a €350 million Sustainability-Linked Bond in 2022, which generated considerable interest among international investors.

Moreover, FIS actively supports the local communities where it operates, funding partnership programmes with schools and universities, cultural initiatives, and youth sports projects.

Looking ahead, FIS aims to grow by further consolidating its leadership in the sector, tackling global health challenges alongside its clients with a responsible, innovative, and highly skilled approach.